JOURNAL OF CARDIAC FAILURE

14(7), S161-S161, Supplement: Suppl. 1, SEP 2008 Title:

Elevated Levels Of Serum Interleukin-12p40 May Reflect Disease Severity Of P atients With Chronic Congestive Heart Failure

Mitsuke Y, Uzui H, Nakano A, Sakata J, Sarazawa K, Ishida K, Satou T, Fujie H, Morishita T, Lee JD.

Division of Cardiology, University of Fukui Hospital, Fukui, Japan

Interleukin(IL)-12p40 is a linchpin immunoregulatory cytokine to promote the development of a Th1 type immune response. To examine whether serum levels of IL-12p40 are increased in patients with CHF and to determine whether a correlation exists between disease severity and serum levels of IL-12p40 of patients with chronic CHF, we assessed the serum levels of IL-12p40 in 56 patients with CHF (LVEF<40%, NYHA II-III) and age-matched 20 healthy volunteers using enzyme-linked immunosorbent assay. Results: The serum levels of IL-12p40 were significantly higher in CHF patients than in healthy volunteer (81.3±8.1 vs 25.7 ±2.9 ng/ml, p<0.01). The serum levels of IL-12p40 showed significant positive correlations with NYHA functional class, serum levels of tumor necrotic factor-alpha, IL-1beta, IL-6, and BNP in patients with CHF. Cardiac death and rehospitalization due to worsening heart failure occurred more frequently in a high serum levels of IL-12p40 group (>54.0ng/ml,n=28) of CHF patients than in a low serum levels of IL-12p40 group (<54.0ng/ml,n=28) for a mean follow-up period of 27.5 months. Furthermore, serially measured serum levels of IL-12p40 decreased significantly along with improvement in NYHA class under medication with carvedilol in 12 patients. Conclusions: Our data showed that the circulating IL-12p40 levels may relate to severity of patients with heart failure syndrome.